Olivier Hermine

机构：Délégation Paris 5, Hôpital Necker-Enfants Malades, Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Institut Necker Enfants Malades, Université Sorbonne Paris Nord, Sorbonne Paris Cité, AB Science (France), Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Laboratoire National de Référence, Délégation Paris 6, Biologie intégrée du globule rouge et de l'Erythropoïèse, Institut des Maladies Génétiques Imagine · ORCID：0000-0003-2574-3874

发表论文 1820 篇 · 总被引 66332 次 · h-index 136

代表论文

• Prognostic Factors Influencing the Efficacy and Safety of Teclistamab and Elranatamab in Multiple Myeloma: A Multicenter Propensity-Weighted Analysis (2026 · JCO oncology advances. · 被引 1)
• NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction (2026 · Nature Communications · 被引 1)
• Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: A subgroup analysis optimizing the benefit-risk profile of masitinib (2025 · medRxiv · 被引 1)
• Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosis (2026 · bioRxiv (Cold Spring Harbor Laboratory))
• Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor (2026 · Journal of Clinical Oncology)
• Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study (2026 · Clinical Lymphoma Myeloma & Leukemia)